Skip to main content

AHEP1531 AHEP1531 Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) - A Phase 2/3 Study

NCT03533582

AHEP1531 Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) - A Phase 2/3 Study

Associated Conditions

Liver Cancer

Principal Investigator

Sponsor

Children's Oncology Group

Because hepatoblastomas are rare tumors, it has been difficult to progress research in this area. However, in this study, Children's Oncology Group will partner with other research groups in Europe and Japan to combine efforts to study the treatment of patients with HB. In this study, the researchers want to find out if we can improve the treatment for subjects (people who agree to take part in this study) with HB. This study uses 'risk assignment' to define your risk group. From past studies, the researchers think that HB patients can be assigned to different risk groups - very low, low, intermediate, or high risk. This is done by looking at factors like age, where the tumor is in the liver, and the level of a certain tumor marker at diagnosis. The risk group you are in is used to guide the treatment you will receive.

This study is currently enrolling.